Cytodyn Inc (CYDY)

[gestalt2]

just for fun, here is a sequence of headline milestones for ibalizumab over the past couple years. align the dates with the chart and we can see what the SP might do as we achieve these milestones. P3 data results for them was in early feb - that is when the SP was at $3.5/share, now at $7.75/share.

•May 3, 2017
Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

•March 6, 2017
Theratechnologies Acquires Commercial Rights to Ibalizumab in the European Union and Four Additional Territories

•February 14, 2017
Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

•January 17, 2017
Theratechnologies Inc.: Ibalizumab 24-Week Pivotal Phase III Study Results Accepted as a Late Breaker Will Be Presented at CROI 2017

•August 18, 2016
Ibalizumab Phase III Study Primary End-Point Results to Be Presented at IDWeek 2016

•May 24, 2016
Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial

•April 27, 2016
Theratechnologies Announces Completion of Enrollment for Phase III Ibalizumab Trial

•March 18, 2016
Theratechnologies and TaiMed Biologics Sign Exclusive Marketing and Distribution Agreement for Ibalizumab